Evidence map›Paper›PMID 33392513›Full record

ReviewBlood cancer discovery2020

Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia.

Ute Fischer, Jun J Yang, Tomokatsu Ikawa, Daniel Hein, Carolina Vicente-Dueñas, Arndt Borkhardt, Isidro Sánchez-García

Open access · bronzeAbstract readReview
In one paragraph

Review in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Immunoenhancing Effects ofJournal of microbiology and biotechnology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Ute FischerDepartment of Pediatric Oncology, Hematology and Clinical Immuno-logy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. isg@usal.es Ute.Fischer@med.uni-duesseldorf.de.
Jun J YangHematological Malignancies Programme, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Tomokatsu IkawaDivision of Immunobiology, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Daniel HeinDepartment of Pediatric Oncology, Hematology and Clinical Immuno-logy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Carolina Vicente-DueñasInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0002-5401-8295
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immuno-logy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Isidro Sánchez-GarcíaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. isg@usal.es Ute.Fischer@med.uni-duesseldorf.de.
Heinrich Heine University Düsseldorf · DEInstituto de Investigación Biomédica de Salamanca · ESSt. Jude Children's Research Hospital · USTokyo University of Science · JP

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Pathogenesis of ETV6-Related Acute Lymphoblastic LeukemiaR01CA241452 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2020 to 2025
$2.6M
ARID5B and disparities of childhood leukemiaU01CA176063 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2014 to 2018
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA241452NCI NIH HHS U01 CA176063NIGMS NIH HHS P50 GM115279
6 · The paper itself

Abstract

B-cells are an integral part of the adaptive immune system and regulate innate immunity. Derived from hematopoietic stem cells they mature through a series of cell fate decisions. Complex transcriptional circuits form and dissipate dynamically during these lineage restrictions. Genomic aberrations of involved transcription factors underlie various B-cell disorders. Acquired somatic aberrations are associated with cancer, whereas germline variations predispose to both malignant and non-malignant diseases. We review the opposing role of transcription factors during B-cell development in health and disease. We focus on early B-cell leukemia and discuss novel causative gene-environment cooperations and their implications for precision medicine.

Indexed as

B-LymphocytesLeukemiaTranscription FactorsCell DifferentiationGene-Environment InteractionHematopoiesisHematopoietic Stem CellsHumansTranscription FactorsB-cellchildhood leukemiaenvironmentgermlinemouse modelssomaticTranscription factors

Identifiers

PMID33392513
PMCPMC7774874
OpenAlexW3085908985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.